ABSTRACT
Pleural empyema formation is one of the potential complications of lower respiratory tract infections and it is characterized by bacterial organisms seen on gram stain or the aspiration of pus on thoracentesis. Very rarely empyema can be caused by trichomonas species, of which Trichomonas Tenax appears to be the most common cause. In this article we report the case of a 51-year-old man who developed a pleural empyema caused by trichomonas, and review the available literature of this rare infection of unknown incidence and uncertain pathogenetic significance. Our patient was treated with metronidazole, however complete cure was not achieved and pulmonary decortication was necessary for the successful outcome. As far as we know, this is the first case of pleural empyema caused by trichomonas reported in Chile.
La formación de un empiema pleural es una de las potenciales complicaciones de las infecciones de la vía aérea inferior, y se caracteriza por la observación de bacterias en la tinción de Gram, o la aspiración de pus en la toracocentesis. Muy infrecuentemente el empiema puede ser causado por alguna de las especies de tricomonas, de las cuales Trichomonas Tenax parece ser la causa más común. En este artículo, reportamos el caso de un hombre de 51 años que desarrolló un empiema pleural causado por tricomonas, y revisamos la literatura disponible de esta rara infección, de incidencia desconocida, y significancia patogénica incierta. Nuestro paciente fue tratado con metronidazol, observándose sólo una respuesta parcial, necesitándose decorticación pulmonar para una recuperación completa. Hasta donde sabemos, este es el primer caso de empiema pleural causado por tricomonas reportado en Chile.
Subject(s)
Humans , Male , Middle Aged , Empyema, Pleural/etiology , Empyema, Pleural/therapy , Trichomonas Infections/complications , Trichomonas Infections/therapy , Antitrichomonal Agents/therapeutic use , Drainage , Empyema, Pleural/surgery , Empyema, Pleural/parasitology , Empyema, Pleural/drug therapy , Metronidazole/therapeutic use , Thoracostomy , Trichomonas Infections/surgery , Trichomonas Infections/drug therapySubject(s)
Amebiasis/drug therapy , Amebicides/therapeutic use , Antitrichomonal Agents/therapeutic use , Giardiasis/drug therapy , Leishmaniasis/drug therapy , Trichomonas Infections/drug therapy , Trypanocidal Agents/therapeutic use , Trypanosomiasis/drug therapy , Antiprotozoal Agents/therapeutic use , Structure-Activity RelationshipABSTRACT
Eight isolates of T. vaginalis obtained from clinical specimens were tested for their pathogenicity in the murine model using the subcutaneous route of inoculation. In general, all isolates produced localised purulent abscesses in the mice. On comparison with a reference strain, all but two isolates were found to be significantly more pathogenic for mice than the reference strain, while two were comparable in their pathogenicity. All eight isolates were sensitive in vivo to metronidazole. In six of the eight isolates, metronidazole (30 mg/kg body wt) administered for four days to subcutaneously infected mice effected a 100 per cent cure. The ED50 values ranged from 3.4 to 23.94 mg/kg body weight. None of the isolates could be termed as resistant.
Subject(s)
Animals , Disease Models, Animal , Female , Male , Metronidazole/pharmacology , Mice , Trichomonas Infections/drug therapy , Trichomonas vaginalis/drug effects , VirulenceABSTRACT
A case vaginitis emphysematosa is presented, wich, with only more 170 cases in the world literature, is the second to be described in Brazilian literature, is thes second to be described in Brazilian literature. This case is associated with idiophatic trombocitopenic purpura, cardiovascular disease and Trichomonas vaginalis vaginitis. The clinical aspects of this vaginitis can suggest that vlood stagnation in vaginal and cervical wall have great importance in the genesis of this situation
Subject(s)
Adult , Humans , Female , Emphysema/complications , Trichomonas Infections/complications , Vaginitis/diagnosis , Biopsy , Metronidazole/therapeutic use , Tinidazole/therapeutic use , Trichomonas Infections/drug therapy , Vaginitis/pathology , Vaginitis/physiopathologyABSTRACT
2868 pacientes adultos de sexo masculino fueron tratados por uretritis gonocócica aguda entre abril de 1981 y abril de 1984 con diferentes esquemas terapéuticos de una dosis única o múltiple. Luego del examen clínico bacteriológico (hisopado uretral y cultivos) y reacciones de V.D.R.L. cualucuantitativas, todos los pacientes recibieron tratamiento. Debieron retornar a un primer control postratamiento entre las 48 y 72 horas. Un segundo control fue programado para el séptimo día después del primer control y la VRDL cuali-cuantitativa repetida a los 30 días postratamiento. El control postratamiento alejado de VDRL (30 días) se pudo realizar solo en el 69 por ciento de los pacientes que concurrieron al segundo control y se detectaron siete nuevos casos reactivos con los controle serológicos. En los casos donde coexistía gonorrea y tricomoniasis, esta última enfermedad fue tratada primero con una dosis única de imidazólicos
Subject(s)
Adult , Humans , Male , Anti-Bacterial Agents/therapeutic use , Gonorrhea/drug therapy , Trichomonas Infections/drug therapy , Urethritis/drug therapy , Acute Disease , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Cefotaxime/therapeutic use , Ceftriaxone/therapeutic use , Follow-Up Studies , Gonorrhea/complications , Gonorrhea/diagnosis , Mezlocillin/therapeutic use , Probenecid/therapeutic use , Recurrence , Urethritis/diagnosis , Urethritis/etiologyABSTRACT
Thirty male patients suffering from symptomatic trichomoniasis and urethra and/or prostate, of different age groups were clinically and laboratory examined. Twenty five cases were completely cured using one single oral dose of Tinidazol tablets [2 gm]. Additional three cases were cured by using two doses of the same drug [each dose was2 gm] with one week interval. Two cases failed to respond after two successive doses of the drug. The drug was excellently tolerated. The author is grateful to the Medical Department of Pfizer Egypt for providing the material for this study